In late November 2018, NetScientific announced that its portfolio company PDS Biotechnology and Edge Therapeutics (NASDAQ: EDGE) will merge. The new entity will trade on the NASDAQ and PDS’s shareholders will maintain majority ownership with a 70% stake, whereas Edge’s shareholders will hold the remaining 30%. The transaction is expected to close in Q119 and NetScientific’s ownership is expected to decrease to 9.2% (from 13.1%). The newly formed entity says it intends to use
30 Nov 2018
NetScientific - PDS agrees to merge with Edge Therapeutics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
NetScientific - PDS agrees to merge with Edge Therapeutics
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
30 Nov 2018 -
Author:
Maxim Jacobs -
Pages:
4
In late November 2018, NetScientific announced that its portfolio company PDS Biotechnology and Edge Therapeutics (NASDAQ: EDGE) will merge. The new entity will trade on the NASDAQ and PDS’s shareholders will maintain majority ownership with a 70% stake, whereas Edge’s shareholders will hold the remaining 30%. The transaction is expected to close in Q119 and NetScientific’s ownership is expected to decrease to 9.2% (from 13.1%). The newly formed entity says it intends to use